<DOC>
	<DOCNO>NCT02455999</DOCNO>
	<brief_summary>The aim pilot study compare analgesic effect two strength SYL1001 eye drop versus placebo patient ocular pain associate Dry Eye Syndrome . General local tolerability also evaluate .</brief_summary>
	<brief_title>Dose-finding Study Assess Safety Effect SYL1001 Patients With Ocular Pain</brief_title>
	<detailed_description />
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Eye Pain</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Give write informed consent participate study , receive information relate design , aim possible risk result therefrom . Common symptoms persistent , daily , mild moderate dry eye last three month : OSDI scale 1370 VAS scale 2 7 . Eye test eye : Corneal fluorescein stain ( Oxford scale &gt; 0 ) , Tear breakup time &lt; 10 second Schirmer 's test anaesthesia &lt; 10 mm/5min . Exclusion criterion : Women pregnant breastfeed positive urine pregnancy test . Women commit use medically acceptable method contraception time selection throughout study . Any current , relevant disease , include respiratory disease , cardiovascular disease , endocrine disease , neurological disease , haematological disease , kidney disease , oncological disease , liver disease , gastrointestinal dysfunction , hypertension active acute infectious process . Previous chronic recurrent process , accord investigator , could affect development study . Concomitant use medication analgesic activity route administration time entry study . Change concomitant eye and/or systemic medication patient one month study study . Changes preestablished administration schedule artificial tear 15 day study 10 day study . Initiation treatment cyclosporine change dosage administration schedule cyclosporine within 6 month inclusion study . History hypersensitivity drug . Use contact lens treatment previous 15 day . History drug abuse drug alcohol dependence . Laboratory abnormality , investigator 's opinion , clinically significant . Previous refractive surgery . Having participate another clinical trial within 2 month prior inclusion . Another eye disease significant investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>